Crowdonomics
All companies

216 Pharmacy Corp

Raising nowOperating

Retail & Consumer · Scottsdale, AZ

216 Pharmacy is building a specialty pharmacy that dispenses high-cost medications, mainly HIV treatments plus oncology and GLP-1 drugs. Planned services include compounding, 340B contract services, telehealth and patient support. It targets chronic-condition patients aged 18-65, starting in Phoenix.

Raising nowRaising now

This company has an open fundraising round.

$0 raised
View the live round
Estimated pre-money ⓘ
$45.0M
As of Sep 2025 · from Reg A Offering (2025) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$0
Across 1 round since 2025
Latest share price
$1.50
Reg A+ · Equity · Sep 2025 offering price

Financials

FY2024 · from SEC filings · hover any figure for its source
$0
−$57K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2024 unaudited
Income statement
Revenue
$0
Cost of goods sold
$0
Net income
-$57,237
Balance sheet
Cash
$3,975
Accounts receivable
$10,283
Total assets
$14,258
Long-term debt
$0
Total liabilities
$22,895
Other
Headcount
0

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$45.0M
est. pre-money
Reg A+ · Equity · Sep 2025

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Aug 29, 2025
Common Stock · 100.0%Preferred Stock · 0%
ClassOutstandingVotes / shareShare of totalLiquidationLast price
Common Stock30,000,0001100.0%paid 2nd$1.50Sep 2025
Preferred Stockpreferred(as of Jun 30, 2025)1—0%——
Total30,000,001100%

Principal holders% as the filing states it, Aug 29, 2025

  • Danny Williamson18,000,000 Common Stock60.0%of company
  • Cabite Entertainment, LLC6,000,000 Common Stock20.0%of company
  • Global Media Network USA, Inc.6,000,000 Common Stock20.0%of company

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $0 / $15MEst. pre-money $45M

Team

8 people
Danny Williamson
Director, Chief Executive Officer and President
Dennis R Alexander
Director and CFO
Mercedes E. Williams
Director and Vice President of Operations
Orleana S. Davis
Treasurer
Sabriana Venegas
Secretary
William Cooper
Director, Chairman of the Board of Directors, Director
Terron D. Sims
Director
Wendell Mark Sims Esq.
Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

SEC filings

  • Form QUALIFSep 4, 20259999999994-25-000174
    EDGAR
  • Form 1-A/AAug 29, 20250001096906-25-001446
    EDGAR
  • Form 1-AAug 25, 20250001096906-25-001425
    EDGAR
Source: SEC EDGARCIK 0002082327DEShare price $1.50Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.